FOLH1 and prostate carcinoma: PSMA is a type-II transmembrane glycoprotein, which shows overexpression on the cell surface of prostate carcinoma cells [17] providing new ways of targeted molecular imaging (PSMA PET/CT) and radioligand therapy (PSMA-RLT) [18,19].